Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 6/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2412660 | 0.91 | PDE1A (0.42) | USP14FEN1PDE1APDE1BPDE4A | |
| SCHEMBL2411916 | 0.90 | USP14 (0.46) | USP14PTGDR2FEN1PDE1APDE1B | |
| SCHEMBL2413828 | 0.90 | PDE1A (0.49) | FEN1PDE1APDE1BPDE4APDE4B | |
| SCHEMBL2411253 | 0.87 | RXFP1 (0.45) | FEN1PDE1APDE1BPDE4APDE4B | |
| SCHEMBL2411173 | 0.87 | FEN1 (0.46) | FEN1PDE1APDE1BPDE4APDE4B | |
| SCHEMBL2410466 | 0.85 | FEN1 (0.42) | USP14FEN1PDE1APDE1BPDE4A | |
| SCHEMBL2411216 | 0.84 | PDE1A (0.46) | FEN1PDE1APDE1BPDE4APDE4B | |
| SCHEMBL2408445 | 0.84 | PDE1A (0.47) | FEN1PDE1APDE1BPDE4APDE4B | |
| SCHEMBL2412845 | 0.84 | MAPT (0.45) | PTGDR2FEN1PDE1APDE1BPDE4A | |
| SCHEMBL4187018 | 0.82 | ACHE (0.47) | FEN1PDE1APDE1BPDE4AREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559716-B1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | KANAZAWA HASHIME | 2010-04-15 | — | — | US | disclosed |
| US-7608716-B2 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1559716-A1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | Grelan Pharmaceutical Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | PDE3B, PDE3A, PDE4A | USP14 661/4885PTGDR2 194/4885FEN1 1590/4885 |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | PDE3B, PDE3A, PDE4A | USP14 704/4885PTGDR2 210/4885FEN1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.